Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced that it has acquired Patient Connect, a provider of patient engagement solutions that enable the measurement of clinical and commercial outcomes and inform the advancement of healthcare. 

Patient Connect patient engagement solutions improve patient outcomes by delivering clinical messaging to physicians and pharmacists at the point of patient contact. Clinical messaging is delivered in physician and pharmacist workflows, to help guide patients to better understand their treatment and disease and empower them to make informed healthcare decisions. Patient Connect has a global reach of 834,000 physicians, 600,000 pharmacists and 1,000,000,000 patients, by point of contact. 

From drug discovery, clinical development and portfolio strategy through commercial planning, market access and customer engagement, Clarivate offers a wide variety of solutions providing end-to-end research intelligence to life science organizations. Clarivate real world data (RWD) products paired with Patient Connect insights will provide life science companies with global patient journey information. The acquisition addresses the increasing need for global personalized data that helps life science companies understand patient populations, supports compliant patient journey analyses and brings life-saving treatments to market.  

Mukhtar Ahmed, President, Science Group, Clarivate: “By combining patient journey data, therapeutic area expertise, artificial intelligence and analytics in ways that unlock hidden insights, enable informed decision-making and accelerate innovation, Clarivate empowers life science organizations to make more confident decisions along the entire drug lifecycle. The combination of Patient Connect global patient-level data with the Clarivate customer engagement suite of life science intelligence solutions will fill a critical need for RWD coverage in Europe, the United States, Asia-Pacific and Latin America.” 

Zoe Baker, Founder and Co-CEO, Patient Connect: “This acquisition serves to provide life science firms with insights to inform the advancement of healthcare through integrated patient journey insights, leveraging Clarivate solutions paired with analytics from Patient Connect. The integration of Patient Connect products with Clarivate assets will further facilitate patient engagement, drive behavioral change and empower healthcare professionals to optimize care.” 

Following the successful acquisition and integration of Decision Resources Group (DRG) in 2020, and Bioinfogate earlier this year, Clarivate continues to invest in high-value, real world data, information and deep subject matter and technical expertise. Clarivate will continue to create exceptional value for customers through expanded global offerings focused on integrating patient journey insights found in Clarivate customer engagement solutions with data and analytics from Patient Connect. The acquisition will enable mission-critical information and insights to be delivered to life science organizations, inform the commercialization of life-changing therapies and support life science companies in improving patient outcomes. 

About Clarivate   
Clarivate™ is a global leader in providing solutions to accelerate the lifecycle of innovation. Our bold mission is to help customers solve some of the world’s most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of science and intellectual property. We help customers discover, protect and commercialize their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise. For more information, please visit clarivate.com.   

About Patient Connect 
Patient Connect is an international company specializing in HCP engagement and patient support via digital messaging within the physician’s and pharmacist’s workflows. The physician channel supports HCP decision-making and actions within the natural workflow of a prescribing cycle, including patient selection, Rx choice and facilitation of primary compliance. Since 2004, Patient Connect has supported and empowered patients, across numerous therapeutic areas, encouraging them to make better decisions about their health. Through the pharmacy channel, Patient Connect drives measurably improved patient adherence, supports adjunctive therapy, facilitates patient choice, contributes to real world evidence (RWE) through primary research and matches patients to clinical studies or support programs. At all times, Patient Connect uses clinical data to design and optimize programs, to objectively measure impact; and to provide powerful, patient-level insights. 

Latest news

VitalConnect Secures over $30 Million in Oversubscribed Series F Financing
July 18, 2023

SAN JOSE, Calif.–(BUSINESS WIRE)–VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, today announced closing on an oversubscribed […]

CurvaFix Closes $39 Million Series C Financing Round Led by MVM Partners and Announces CEO Transition
July 14, 2023

BELLEVUE, Wash.–(BUSINESS WIRE)–CurvaFix, Inc., a developer of medical devices to repair fractures in curved bones, today announced the close of […]

Vertos Medical Secures $26 Million to Expand Commercialization Efforts and Develop Breakthrough Treatments for Chronic Low Back Pain
June 7, 2023

ALISO VIEJO, Calif., June 7, 2023 /PRNewswire/ — Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for […]

eXmoor pharma completes $35 million Series A to expand cell and gene therapy manufacturing capabilities
May 30, 2023

New GMP facility to complete eXmoor’s transition from consultancy to one-stop global cell and gene therapy partner Bristol, UK, May […]

GT Medical Technologies Raises $45 Million in Oversubscribed Series C Financing
March 23, 2023

TEMPE, Ariz., March 23, 2023 /PRNewswire/ — GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients […]

OSSIO Launches World’s First and Only Non-Permanent Compression Staple
February 7, 2023

OSSIOfiber® Compression Staple Answers Surgeon, Patient Demand in Fastest Growing Product Category in Extremities WOBURN, Mass.–(BUSINESS WIRE)–OSSIO, Inc., a fast-growing orthopedic fixation […]

VERO Biotech’s Second Generation GENOSYL® Delivery System (DS) Receives FDA Approval in Anesthesia in the Surgical Suite
February 6, 2023

Second Generation GENOSYL® DS is the first and only Inhaled Nitric Oxide delivery system that is FDA-approved for rebreathing anesthesia, […]

VERO Biotech Receives FDA Approval of its Third Generation Tankless Inhaled Nitric Oxide Delivery System
January 9, 2023

VERO Biotech Inc., a commercial-stage healthcare business dedicated to neonatal intensive care and the acute care hospital community, today announced […]

MVM Closes Oversubscribed Fund at $500 Million Hard Cap
November 14, 2022

BOSTON & LONDON — MVM Partners is pleased to announce the closing of its sixth healthcare fund, MVM VI, with […]

MVM Invests in Ossio
October 18, 2022

Proceeds will be used to strengthen awareness for the patient benefits of bio-integrative OSSIOfiber® implants and accelerate new product platforms into the major […]